GSK moves into New Oxford Street office in boost for central London Pharma GSK has opened the doors to its new West End office - called the Earnshaw.
US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots Healthcare Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.
Election 2024: Firms have ‘nothing to worry about’ on workers’ rights, Reeves says Battle for No10 Rachel Reeves has told businesses they have “nothing to worry about” from Labour’s workers' rights reforms at The Times CEO Summit.
GSK: Good news for pharma giant as approval granted to expand vaccine use June 10, 2024 The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.
GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling June 3, 2024 GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.
GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
GSK raises 2024 guidance after strong vaccine sales May 1, 2024 In its first quarter, British company GSK said sales rose 10 per cent to £7.4bn but total operating profit fell 18 per cent to £1.49bn.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.
GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.
GSK reports robust results from latest trial with injectable HIV treatment February 21, 2024 GSK has today reported favourable findings from the Latitude phase III study of its long-acting injectable antiretroviral treatment (ART) for HIV. The study was conducted by Viiv Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. The company said that an interim analysis of the Latitude [...]